id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-2252-0001,FDA,FDA-2020-N-2252,Interim Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act; Public Meeting; Request for Comments,Notice,Request for Comments,2020-12-28T05:00:00Z,2020,12,2020-12-28T05:00:00Z,2021-03-30T03:59:59Z,2021-03-30T01:00:27Z,2020-28602,0,0,09000064849cc7ab